NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Sees Large Decline in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 11,000 shares, a decline of 50.7% from the January 15th total of 22,300 shares. Based on an average daily trading volume, of 22,800 shares, the days-to-cover ratio is currently 0.5 days.

NRx Pharmaceuticals Stock Performance

NRXPW traded down $0.01 on Thursday, reaching $0.16. The company’s stock had a trading volume of 1,249 shares, compared to its average volume of 43,205. NRx Pharmaceuticals has a fifty-two week low of $0.04 and a fifty-two week high of $0.50. The stock has a 50 day moving average of $0.17 and a two-hundred day moving average of $0.10.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.